Curcumin's Effect on Diabetic Patients With Atherosclerotic Cardiovascular Risk
Diabetes Mellitus, Type 2, Dyslipidemias, Hypertension
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, ASCVD Risk, Curcumin, Inflammation, Oxidative stress, Diabetes complication
Eligibility Criteria
Inclusion Criteria: Adult Male or female patients aged 40 years or older A calculated 10 year ASCVD risk score of 5 % or more Patient previously or newly diagnosed with hypertension Patient previously or newly diagnosed with dyslipidaemia Patients diagnosed as Type 2 diabetes mellitus taking insulin or oral hypoglycemic agent with controlled HbA1c < 10% Willingness and ability to give informed consent. Exclusion Criteria: Congenital or acquired bleeding disorders. Cholelithiasis, gall bladder or biliary tract disease or other active liver diseases. Pregnant or breastfeeding women. Oral hypoglycemic drugs that affect cardiovascular diseases risk. Patients with clinical ASCVD (myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease).
Sites / Locations
- Demerdash Hospital, Faculty of Medicine, Ain Shams UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Group 1, Curcumin group
Group 2, Control group
Group 1, Curcumin group (n=36): Patients will receive conventional treatment co-administrated with Turmeric Curcumin 500 mg thrice daily for 14 weeks.
Group 2, Control group (n= 36): Patients will receive conventional therapy alone for 14 weeks.